Pages

Sunday, November 27, 2011

Ezetimibe And Simvastatin May Reduce Heart Risks In Kidney Disease Patients.

Bloomberg News Share to FacebookShare to Twitter (10/29, Peterson) reported that the drug Vytorin (ezetimibe and simvastatin) "reduces heart risks in patients with kidney disease, according to US regulators weighing whether to approve the expanded use." A clinical trial of the Merck & Co. "drug showed it reduced the risk of 'major vascular events' by 16 percent, compared with a placebo, Food and Drug Administration staff said in a preliminary review Share to FacebookShare to Twitter (pdf) posted...on the agency's website. Outside advisers to the FDA are scheduled to meet Nov. 2 to evaluate the findings."
        Forbes Share to FacebookShare to Twitter (10/31, Husten) reports an "FDA reviewer has generally endorsed the positive interpretation of the SHARP (Study of Heart and Renal Protection) trial of ezetimibe and simvastatin [Vytorin] in chronic kidney disease (CKD)." In an analysis "of SHARP by the FDA reviewer found that the combination of ezetimibe and simvastatin reduced the rate of major vascular events by 16% (p=0.001), compared with placebo."

No comments:

Post a Comment